Therapeutic effects and survival quality of raltitrexed and radiotherapy in esophagus cancer
10.3969/j.issn.1005-1678.2017.01.051
- VernacularTitle:雷替曲塞联合放疗治疗食管癌的临床效果及对生存质量的影响
- Author:
He WU
;
Liming BAO
;
Xiaozhen YING
;
Suzhen LV
;
Yaping XU
- Keywords:
raltitrexed;
radiotherapy;
esophagus cancer;
efficacy;
quality of life
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(1):176-178
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect and survival quality of raltitrexed and radiotherapy in treatment of esophagus cancer. Methods 100 cases with esophagus cancer were selected. There were 50 cases using raltitrexed combined with concurrent radiotherapy as observation group. Others were treated with 5-Fu combined with concurrent radiotherapy as control group. The clinical therapeutic effect and survival situation of two groups were evaluated. Results After treatment, the total response rate of observation group (86.0%) was higher than control group (58.0%), the differences between the two groups was statistical difference(P<0.05).The one- and two-year survival rates in observation group were higher than control group (χ2 = 4.32, 7.954, P=0.038, 0.005<0.05).There was no significant difference between the two groups in incidence rate of acute esophagitis, acute bone marrow suppression and acute skin reaction. Conclusion The clinical therapy of raltitrexed plus radiotherapy in treatment of esophagus cancer is distinct, and improve the survival time and the quality of life of patients.
